Multiple Sclerosis-Pipeline Review, H1 2016

Multiple Sclerosis-Pipeline Review, H1 2016


  • Products Id :- GMDHC7962IDB
  • |
  • Pages: 903
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Multiple Sclerosis-Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Multiple Sclerosis-Pipeline Review, H1 2016', provides an overview of the Multiple Sclerosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Multiple Sclerosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Multiple Sclerosis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Multiple Sclerosis

The report reviews pipeline therapeutics for Multiple Sclerosis by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Multiple Sclerosis therapeutics and enlists all their major and minor projects

The report assesses Multiple Sclerosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Multiple Sclerosis

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Multiple Sclerosis

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Multiple Sclerosis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

Introduction 10

Multiple Sclerosis Overview 11

Therapeutics Development 12

Multiple Sclerosis-Therapeutics under Development by Companies 14

Multiple Sclerosis-Therapeutics under Investigation by Universities/Institutes 30

Multiple Sclerosis-Pipeline Products Glance 32

Multiple Sclerosis-Products under Development by Companies 36

Multiple Sclerosis-Products under Investigation by Universities/Institutes 56

Multiple Sclerosis-Companies Involved in Therapeutics Development 59

Multiple Sclerosis-Therapeutics Assessment 237

Drug Profiles 290

Multiple Sclerosis-Dormant Projects 828

Multiple Sclerosis-Discontinued Products 852

Multiple Sclerosis-Product Development Milestones 857

Appendix 868

List of Figures

Number of Products under Development for Multiple Sclerosis, H1 2016 46

Number of Products under Development for Multiple Sclerosis-Comparative Analysis, H1 2016 47

Number of Products under Development by Companies, H1 2016 48

Number of Products under Investigation by Universities/Institutes, H1 2016 64

Comparative Analysis by Late Stage Development, H1 2016 66

Comparative Analysis by Clinical Stage Development, H1 2016 67

Comparative Analysis by Early Stage Products, H1 2016 68

Assessment by Monotherapy Products, H1 2016 271

Assessment by Combination Products, H1 2016 272

Number of Products by Top 10 Targets, H1 2016 273

Number of Products by Stage and Top 10 Targets, H1 2016 273

Number of Products by Top 10 Mechanism of Actions, H1 2016 302

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 302

Number of Products by Top 10 Routes of Administration, H1 2016 320

Number of Products by Stage and Top 10 Routes of Administration, H1 2016 320

Number of Products by Top 10 Molecule Types, H1 2016 322

Number of Products by Stage and Top 10 Molecule Types, H1 2016 322

List of Tables

Number of Products under Development for Multiple Sclerosis, H1 2016 46

Number of Products under Development for Multiple Sclerosis-Comparative Analysis, H1 2016 47

Number of Products under Development by Companies, H1 2016 49

Number of Products under Development by Companies, H1 2016 (Contd..1) 50

Number of Products under Development by Companies, H1 2016 (Contd..2) 51

Number of Products under Development by Companies, H1 2016 (Contd..3) 52

Number of Products under Development by Companies, H1 2016 (Contd..4) 53

Number of Products under Development by Companies, H1 2016 (Contd..5) 54

Number of Products under Development by Companies, H1 2016 (Contd..6) 55

Number of Products under Development by Companies, H1 2016 (Contd..7) 56

Number of Products under Development by Companies, H1 2016 (Contd..8) 57

Number of Products under Development by Companies, H1 2016 (Contd..9) 58

Number of Products under Development by Companies, H1 2016 (Contd..10) 59

Number of Products under Development by Companies, H1 2016 (Contd..11) 60

Number of Products under Development by Companies, H1 2016 (Contd..12) 61

Number of Products under Development by Companies, H1 2016 (Contd..13) 62

Number of Products under Development by Companies, H1 2016 (Contd..14) 63

Number of Products under Investigation by Universities/Institutes, H1 2016 64

Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..1) 65

Comparative Analysis by Late Stage Development, H1 2016 66

Comparative Analysis by Clinical Stage Development, H1 2016 67

Comparative Analysis by Early Stage Development, H1 2016 68

Comparative Analysis by Unknown Stage Development, H1 2016 69

Products under Development by Companies, H1 2016 70

Products under Development by Companies, H1 2016 (Contd..1) 71

Products under Development by Companies, H1 2016 (Contd..2) 72

Products under Development by Companies, H1 2016 (Contd..3) 73

Products under Development by Companies, H1 2016 (Contd..4) 74

Products under Development by Companies, H1 2016 (Contd..5) 75

Products under Development by Companies, H1 2016 (Contd..6) 76

Products under Development by Companies, H1 2016 (Contd..7) 77

Products under Development by Companies, H1 2016 (Contd..8) 78

Products under Development by Companies, H1 2016 (Contd..9) 79

Products under Development by Companies, H1 2016 (Contd..10) 80

Products under Development by Companies, H1 2016 (Contd..11) 81

Products under Development by Companies, H1 2016 (Contd..12) 82

Products under Development by Companies, H1 2016 (Contd..13) 83

Products under Development by Companies, H1 2016 (Contd..14) 84

Products under Development by Companies, H1 2016 (Contd..15) 85

Products under Development by Companies, H1 2016 (Contd..16) 86

Products under Development by Companies, H1 2016 (Contd..17) 87

Products under Development by Companies, H1 2016 (Contd..18) 88

Products under Development by Companies, H1 2016 (Contd..19) 89

Products under Investigation by Universities/Institutes, H1 2016 90

Products under Investigation by Universities/Institutes, H1 2016 (Contd..1) 91

Products under Investigation by Universities/Institutes, H1 2016 (Contd..2) 92

Multiple Sclerosis-Pipeline by 4D Pharma Plc, H1 2016 93

Multiple Sclerosis-Pipeline by 4SC AG, H1 2016 94

Multiple Sclerosis-Pipeline by AB Science SA, H1 2016 95

Multiple Sclerosis-Pipeline by AbbVie Inc., H1 2016 96

Multiple Sclerosis-Pipeline by Ablynx NV, H1 2016 97

Multiple Sclerosis-Pipeline by Acorda Therapeutics, Inc., H1 2016 98

Multiple Sclerosis-Pipeline by Actelion Ltd, H1 2016 99

Multiple Sclerosis-Pipeline by Addex Therapeutics Ltd, H1 2016 100

Multiple Sclerosis-Pipeline by Adhaere Pharmaceuticals, Inc., H1 2016 101

Multiple Sclerosis-Pipeline by Aegis Therapeutics, LLC, H1 2016 102

Multiple Sclerosis-Pipeline by Affectis Pharmaceuticals AG, H1 2016 103

Multiple Sclerosis-Pipeline by AiCuris GmbH & Co. KG, H1 2016 104

Multiple Sclerosis-Pipeline by Alkermes Plc, H1 2016 105

Multiple Sclerosis-Pipeline by Alpha Cancer Technologies Inc., H1 2016 106

Multiple Sclerosis-Pipeline by Amarna Therapeutics B.V., H1 2016 107

Multiple Sclerosis-Pipeline by Anavex Life Sciences Corp., H1 2016 108

Multiple Sclerosis-Pipeline by Antisense Therapeutics Limited, H1 2016 109

Multiple Sclerosis-Pipeline by Antitope Limited, H1 2016 110

Multiple Sclerosis-Pipeline by Aphios Corporation, H1 2016 111

Multiple Sclerosis-Pipeline by Apitope International NV, H1 2016 112

Multiple Sclerosis-Pipeline by Arena Pharmaceuticals, Inc., H1 2016 113

Multiple Sclerosis-Pipeline by Argos Therapeutics, Inc., H1 2016 114

Multiple Sclerosis-Pipeline by Arrien Pharmaceuticals, LLC, H1 2016 115

Multiple Sclerosis-Pipeline by Artielle ImmunoTherapeutics, Inc., H1 2016 116

Multiple Sclerosis-Pipeline by Astellas Pharma Inc., H1 2016 117

Multiple Sclerosis-Pipeline by Asterias Biotherapeutics, Inc., H1 2016 118

Multiple Sclerosis-Pipeline by Atara Biotherapeutics, Inc., H1 2016 119

Multiple Sclerosis-Pipeline by Athersys, Inc., H1 2016 120

Multiple Sclerosis-Pipeline by Axxam SpA, H1 2016 121

Multiple Sclerosis-Pipeline by Baliopharm AG, H1 2016 122

Multiple Sclerosis-Pipeline by Bio-Cancer Treatment International Limited, H1 2016 123

Multiple Sclerosis-Pipeline by BioAegis Therapeutics, Inc., H1 2016 124

Multiple Sclerosis-Pipeline by BIOCAD, H1 2016 125

Multiple Sclerosis-Pipeline by Biocon Limited, H1 2016 126

Multiple Sclerosis-Pipeline by Biogen, Inc., H1 2016 127

Multiple Sclerosis-Pipeline by Biogenomics Limited, H1 2016 128

Multiple Sclerosis-Pipeline by Biokine Therapeutics Ltd., H1 2016 129

Multiple Sclerosis-Pipeline by Biomar Microbial Technologies, H1 2016 130

Multiple Sclerosis-Pipeline by Bionature E.A. Ltd., H1 2016 131

Multiple Sclerosis-Pipeline by Bioncotech Therapeutics S.L., H1 2016 132

Multiple Sclerosis-Pipeline by Bionovis SA, H1 2016 133

Multiple Sclerosis-Pipeline by Bionure Farma, S.L., H1 2016 134

Multiple Sclerosis-Pipeline by Biovista Inc., H1 2016 135

Multiple Sclerosis-Pipeline by Bird Rock Bio, Inc., H1 2016 136

Multiple Sclerosis-Pipeline by Bolder Biotechnology, Inc., H1 2016 137

Multiple Sclerosis-Pipeline by BrainStorm Cell Therapeutics Inc., H1 2016 138

Multiple Sclerosis-Pipeline by C4X Discovery Holdings PLC, H1 2016 139

Multiple Sclerosis-Pipeline by Caladrius Biosciences, Inc. , H1 2016 140

Multiple Sclerosis-Pipeline by CASI Pharmaceuticals Inc., H1 2016 141

Multiple Sclerosis-Pipeline by Catalyst Pharmaceuticals, Inc., H1 2016 142

Multiple Sclerosis-Pipeline by Celgene Corporation, H1 2016 143

Multiple Sclerosis-Pipeline by Cell Cure Neurosciences, Ltd., H1 2016 144

Multiple Sclerosis-Pipeline by Cell2B S.A. , H1 2016 145

Multiple Sclerosis-Pipeline by Cellceutix Corporation, H1 2016 146

Multiple Sclerosis-Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2016 147

Multiple Sclerosis-Pipeline by Cognosci, Inc., H1 2016 148

Multiple Sclerosis-Pipeline by Coherus BioSciences, Inc., H1 2016 149

Multiple Sclerosis-Pipeline by Commence Bio, Inc., H1 2016 150

Multiple Sclerosis-Pipeline by Compugen Ltd., H1 2016 151

Multiple Sclerosis-Pipeline by Connexios Life Sciences Pvt. Ltd., H1 2016 152

Multiple Sclerosis-Pipeline by Critical Outcome Technologies Inc., H1 2016 153

Multiple Sclerosis-Pipeline by CuraVac, Inc., H1 2016 154

Multiple Sclerosis-Pipeline by Cyxone AB, H1 2016 155

Multiple Sclerosis-Pipeline by Dimerix Bioscience Pty Ltd, H1 2016 156

Multiple Sclerosis-Pipeline by Eisai Co., Ltd., H1 2016 157

Multiple Sclerosis-Pipeline by Endece, LLC, H1 2016 158

Multiple Sclerosis-Pipeline by Euroscreen S.A., H1 2016 159

Multiple Sclerosis-Pipeline by Evgen Pharma Plc, H1 2016 160

Multiple Sclerosis-Pipeline by Evotec AG, H1 2016 161

Multiple Sclerosis-Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 162

Multiple Sclerosis-Pipeline by Flex Pharma, Inc., H1 2016 163

Multiple Sclerosis-Pipeline by Forward Pharma A/S, H1 2016 164

Multiple Sclerosis-Pipeline by FPRT Bio Inc., H1 2016 165

Multiple Sclerosis-Pipeline by Gemac, H1 2016 166

Multiple Sclerosis-Pipeline by Genervon Biopharmaceuticals, LLC, H1 2016 167

Multiple Sclerosis-Pipeline by GeNeuro SA, H1 2016 168

Multiple Sclerosis-Pipeline by Genzyme Corporation, H1 2016 169

Multiple Sclerosis-Pipeline by GlaxoSmithKline Plc, H1 2016 170

Multiple Sclerosis-Pipeline by Glialogix, Inc., H1 2016 171

Multiple Sclerosis-Pipeline by Hansa Medical AB, H1 2016 172

Multiple Sclerosis-Pipeline by Hanwha Chemical Corporation, H1 2016 173

Multiple Sclerosis-Pipeline by Harbor Therapeutics, Inc., H1 2016 174

Multiple Sclerosis-Pipeline by HitGen LTD, H1 2016 175

Multiple Sclerosis-Pipeline by Hutchison MediPharma Limited, H1 2016 176

Multiple Sclerosis-Pipeline by Iltoo Pharma, H1 2016 177

Multiple Sclerosis-Pipeline by Immune Response BioPharma, Inc., H1 2016 178

Multiple Sclerosis-Pipeline by ImmuNext, Inc., H1 2016 179

Multiple Sclerosis-Pipeline by Immungenetics AG, H1 2016 180

Multiple Sclerosis-Pipeline by InDex Pharmaceuticals AB, H1 2016 181

Multiple Sclerosis-Pipeline by Innate Immunotherapeutics Ltd, H1 2016 182

Multiple Sclerosis-Pipeline by Inovio Pharmaceuticals, Inc., H1 2016 183

Multiple Sclerosis-Pipeline by Io Therapeutics, Inc., H1 2016 184

Multiple Sclerosis-Pipeline by Jyant Technologies, Inc., H1 2016 185

Multiple Sclerosis-Pipeline by Kadimastem Ltd., H1 2016 186

Multiple Sclerosis-Pipeline by Kadmon Corporation, LLC, H1 2016 187

Multiple Sclerosis-Pipeline by KAHR medical Ltd., H1 2016 188

Multiple Sclerosis-Pipeline by KaloBios Pharmaceuticals, Inc., H1 2016 189

Multiple Sclerosis-Pipeline by Kareus Therapeutics, SA, H1 2016 190

Multiple Sclerosis-Pipeline by Karo Pharma AB, H1 2016 191

Multiple Sclerosis-Pipeline by Karyopharm Therapeutics, Inc., H1 2016 192

Multiple Sclerosis-Pipeline by Kezar Life Sciences, Inc., H1 2016 193

Multiple Sclerosis-Pipeline by Kineta, Inc., H1 2016 194

Multiple Sclerosis-Pipeline by Kyorin Pharmaceutical Co., Ltd., H1 2016 195

Multiple Sclerosis-Pipeline by Lead Discovery Center GmbH, H1 2016 196

Multiple Sclerosis-Pipeline by LFB S.A., H1 2016 197

Multiple Sclerosis-Pipeline by Lipocure Ltd., H1 2016 198

Multiple Sclerosis-Pipeline by MacroGenics, Inc., H1 2016 199

Multiple Sclerosis-Pipeline by MAKScientific, LLC, H1 2016 200

Multiple Sclerosis-Pipeline by Mallinckrodt Plc, H1 2016 201

Multiple Sclerosis-Pipeline by Mapi Pharma Ltd., H1 2016 202

Multiple Sclerosis-Pipeline by Marathon Pharmaceuticals, LLC, H1 2016 203

Multiple Sclerosis-Pipeline by MedAnnex Ltd, H1 2016 204

Multiple Sclerosis-Pipeline by MedDay SA, H1 2016 205

Multiple Sclerosis-Pipeline by Medestea Research & Production S.p.A., H1 2016 206

Multiple Sclerosis-Pipeline by MedImmune, LLC, H1 2016 207

Multiple Sclerosis-Pipeline by Meiji Seika Pharma Co., Ltd., H1 2016 208

Multiple Sclerosis-Pipeline by Merck KGaA, H1 2016 209

Multiple Sclerosis-Pipeline by Meta-IQ ApS, H1 2016 210

Multiple Sclerosis-Pipeline by Mitochon Pharmaceuticals, Inc., H1 2016 211

Multiple Sclerosis-Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2016 212

Multiple Sclerosis-Pipeline by MorphoSys AG, H1 2016 213

Multiple Sclerosis-Pipeline by Neuralstem, Inc., H1 2016 214

Multiple Sclerosis-Pipeline by Neuren Pharmaceuticals Limited, H1 2016 215

Multiple Sclerosis-Pipeline by Neurotec Pharma SL, H1 2016 216

Multiple Sclerosis-Pipeline by New World Laboratories, Inc., H1 2016 217

Multiple Sclerosis-Pipeline by Novartis AG, H1 2016 218

Multiple Sclerosis-Pipeline by NovImmune SA, H1 2016 219

Multiple Sclerosis-Pipeline by Nuevolution AB, H1 2016 220

Multiple Sclerosis-Pipeline by Octapharma AG, H1 2016 221

Multiple Sclerosis-Pipeline by Omeros Corporation, H1 2016 222

Multiple Sclerosis-Pipeline by OncoImmune, Inc., H1 2016 223

Multiple Sclerosis-Pipeline by Opexa Therapeutics, Inc., H1 2016 224

Multiple Sclerosis-Pipeline by OPKO Health, Inc., H1 2016 225

Multiple Sclerosis-Pipeline by OSE Immunotherapeutics, H1 2016 226

Multiple Sclerosis-Pipeline by Parvus Therapeutics, Inc., H1 2016 227

Multiple Sclerosis-Pipeline by Peptinov SAS, H1 2016 228

Multiple Sclerosis-Pipeline by Pfenex Inc., H1 2016 229

Multiple Sclerosis-Pipeline by Pfizer Inc., H1 2016 230

Multiple Sclerosis-Pipeline by PharmaEssentia Corporation, H1 2016 231

Multiple Sclerosis-Pipeline by PharmatrophiX, Inc., H1 2016 232

Multiple Sclerosis-Pipeline by Pharmaxis Limited, H1 2016 233

Multiple Sclerosis-Pipeline by Pieris Pharmaceuticals, Inc., H1 2016 234

Multiple Sclerosis-Pipeline by Plexxikon Inc., H1 2016 235

Multiple Sclerosis-Pipeline by ProNoxis AB, H1 2016 236

Multiple Sclerosis-Pipeline by Prothena Corporation Plc, H1 2016 237

Multiple Sclerosis-Pipeline by Q Therapeutics, Inc., H1 2016 238

Multiple Sclerosis-Pipeline by ReceptoPharm, Inc., H1 2016 239

Multiple Sclerosis-Pipeline by RedHill Biopharma Ltd., H1 2016 240

Multiple Sclerosis-Pipeline by RegeneRx Biopharmaceuticals, Inc., H1 2016 241

Multiple Sclerosis-Pipeline by Regenesance BV, H1 2016 242

Multiple Sclerosis-Pipeline by Resverlogix Corp., H1 2016 243

Multiple Sclerosis-Pipeline by ReveraGen BioPharma, Inc., H1 2016 244

Multiple Sclerosis-Pipeline by Rigel Pharmaceuticals, Inc., H1 2016 245

Multiple Sclerosis-Pipeline by SanBio, Inc., H1 2016 246

Multiple Sclerosis-Pipeline by Santhera Pharmaceuticals Holding AG, H1 2016 247

Multiple Sclerosis-Pipeline by Sareum Holdings Plc, H1 2016 248

Multiple Sclerosis-Pipeline by SK Biopharmaceuticals Co., Ltd., H1 2016 249

Multiple Sclerosis-Pipeline by Sorrento Therapeutics, Inc., H1 2016 250

Multiple Sclerosis-Pipeline by Symic Biomedical, Inc., H1 2016 251

Multiple Sclerosis-Pipeline by Synthon Holdings BV, H1 2016 252

Multiple Sclerosis-Pipeline by Targazyme, Inc., H1 2016 253

Multiple Sclerosis-Pipeline by Teikoku Pharma USA, Inc., H1 2016 254

Multiple Sclerosis-Pipeline by Teva Pharmaceutical Industries Ltd., H1 2016 255

Multiple Sclerosis-Pipeline by Therapix Biosciences Ltd, H1 2016 256

Multiple Sclerosis-Pipeline by TikoMed AB, H1 2016 257

Multiple Sclerosis-Pipeline by Toleranzia AB, H1 2016 258

Multiple Sclerosis-Pipeline by Topas Therapeutics GmbH, H1 2016 259

Multiple Sclerosis-Pipeline by TxCell SA, H1 2016 260

Multiple Sclerosis-Pipeline by Vaccinex, Inc., H1 2016 261

Multiple Sclerosis-Pipeline by Vakzine Projekt Management GmbH, H1 2016 262

Multiple Sclerosis-Pipeline by Vertex Pharmaceuticals Incorporated, H1 2016 263

Multiple Sclerosis-Pipeline by Virogenomics BioDevelopment, Inc., H1 2016 264

Multiple Sclerosis-Pipeline by Vitae Pharmaceuticals, Inc., H1 2016 265

Multiple Sclerosis-Pipeline by VivaCell Biotechnology Espana S.L., H1 2016 266

Multiple Sclerosis-Pipeline by Xenetic Biosciences (UK) Limited, H1 2016 267

Multiple Sclerosis-Pipeline by XL-protein GmbH, H1 2016 268

Multiple Sclerosis-Pipeline by Yungjin Pharm. Co., Ltd., H1 2016 269

Multiple Sclerosis-Pipeline by Zydus Cadila Healthcare Limited, H1 2016 270

Assessment by Monotherapy Products, H1 2016 271

Assessment by Combination Products, H1 2016 272

Number of Products by Stage and Target, H1 2016 274

Number of Products by Stage and Mechanism of Action, H1 2016 303

Number of Products by Stage and Route of Administration, H1 2016 321

Number of Products by Stage and Molecule Type, H1 2016 323

Multiple Sclerosis-Dormant Projects, H1 2016 862

Multiple Sclerosis-Dormant Projects (Contd..1), H1 2016 863

Multiple Sclerosis-Dormant Projects (Contd..2), H1 2016 864

Multiple Sclerosis-Dormant Projects (Contd..3), H1 2016 865

Multiple Sclerosis-Dormant Projects (Contd..4), H1 2016 866

Multiple Sclerosis-Dormant Projects (Contd..5), H1 2016 867

Multiple Sclerosis-Dormant Projects (Contd..6), H1 2016 868

Multiple Sclerosis-Dormant Projects (Contd..7), H1 2016 869

Multiple Sclerosis-Dormant Projects (Contd..8), H1 2016 870

Multiple Sclerosis-Dormant Projects (Contd..9), H1 2016 871

Multiple Sclerosis-Dormant Projects (Contd..10), H1 2016 872

Multiple Sclerosis-Dormant Projects (Contd..11), H1 2016 873

Multiple Sclerosis-Dormant Projects (Contd..12), H1 2016 874

Multiple Sclerosis-Dormant Projects (Contd..13), H1 2016 875

Multiple Sclerosis-Dormant Projects (Contd..14), H1 2016 876

Multiple Sclerosis-Dormant Projects (Contd..15), H1 2016 877

Multiple Sclerosis-Dormant Projects (Contd..16), H1 2016 878

Multiple Sclerosis-Dormant Projects (Contd..17), H1 2016 879

Multiple Sclerosis-Dormant Projects (Contd..18), H1 2016 880

Multiple Sclerosis-Dormant Projects (Contd..19), H1 2016 881

Multiple Sclerosis-Dormant Projects (Contd..20), H1 2016 882

Multiple Sclerosis-Dormant Projects (Contd..21), H1 2016 883

Multiple Sclerosis-Dormant Projects (Contd..22), H1 2016 884

Multiple Sclerosis-Dormant Projects (Contd..23), H1 2016 885

Multiple Sclerosis-Discontinued Products, H1 2016 886

Multiple Sclerosis-Discontinued Products (Contd..1), H1 2016 887

Multiple Sclerosis-Discontinued Products (Contd..2), H1 2016 888

Multiple Sclerosis-Discontinued Products (Contd..3), H1 2016 889

Multiple Sclerosis-Discontinued Products (Contd..4), H1 2016 890

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

4D Pharma Plc

4SC AG

AB Science SA

AbbVie Inc.

Ablynx NV

Acorda Therapeutics, Inc.

Actelion Ltd

Addex Therapeutics Ltd

Adhaere Pharmaceuticals, Inc.

Aegis Therapeutics, LLC

Affectis Pharmaceuticals AG

AiCuris GmbH & Co. KG

Alkermes Plc

Alpha Cancer Technologies Inc.

Amarna Therapeutics B.V.

Anavex Life Sciences Corp.

Antisense Therapeutics Limited

Antitope Limited

Aphios Corporation

Apitope International NV

Arena Pharmaceuticals, Inc.

Argos Therapeutics, Inc.

Arrien Pharmaceuticals, LLC

Artielle ImmunoTherapeutics, Inc.

Astellas Pharma Inc.

Asterias Biotherapeutics, Inc.

Atara Biotherapeutics, Inc.

Athersys, Inc.

Axxam SpA

Baliopharm AG

Bio-Cancer Treatment International Limited

BioAegis Therapeutics, Inc.

BIOCAD

Biocon Limited

Biogen, Inc.

Biogenomics Limited

Biokine Therapeutics Ltd.

Biomar Microbial Technologies

Bionature E.A. Ltd.

Bioncotech Therapeutics S.L.

Bionovis SA

Bionure Farma, S.L.

Biovista Inc.

Bird Rock Bio, Inc.

Bolder Biotechnology, Inc.

BrainStorm Cell Therapeutics Inc.

C4X Discovery Holdings PLC

Caladrius Biosciences, Inc.

CASI Pharmaceuticals Inc.

Catalyst Pharmaceuticals, Inc.

Celgene Corporation

Cell Cure Neurosciences, Ltd.

Cell2B S.A.

Cellceutix Corporation

Chong Kun Dang Pharmaceutical Corp.

Cognosci, Inc.

Coherus BioSciences, Inc.

Commence Bio, Inc.

Compugen Ltd.

Connexios Life Sciences Pvt. Ltd.

Critical Outcome Technologies Inc.

CuraVac, Inc.

Cyxone AB

Dimerix Bioscience Pty Ltd

Eisai Co., Ltd.

Endece, LLC

Euroscreen S.A.

Evgen Pharma Plc

Evotec AG

F. Hoffmann-La Roche Ltd.

Flex Pharma, Inc.

Forward Pharma A/S

FPRT Bio Inc.

Gemac

Genervon Biopharmaceuticals, LLC

GeNeuro SA

Genzyme Corporation

GlaxoSmithKline Plc

Glialogix, Inc.

Hansa Medical AB

Hanwha Chemical Corporation

Harbor Therapeutics, Inc.

HitGen LTD

Hutchison MediPharma Limited

Iltoo Pharma

Immune Response BioPharma, Inc.

ImmuNext, Inc.

Immungenetics AG

InDex Pharmaceuticals AB

Innate Immunotherapeutics Ltd

Inovio Pharmaceuticals, Inc.

Io Therapeutics, Inc.

Jyant Technologies, Inc.

Kadimastem Ltd.

Kadmon Corporation, LLC

KAHR medical Ltd.

KaloBios Pharmaceuticals, Inc.

Kareus Therapeutics, SA

Karo Pharma AB

Karyopharm Therapeutics, Inc.

Kezar Life Sciences, Inc.

Kineta, Inc.

Kyorin Pharmaceutical Co., Ltd.

Lead Discovery Center GmbH

LFB S.A.

Lipocure Ltd.

MacroGenics, Inc.

MAKScientific, LLC

Mallinckrodt Plc

Mapi Pharma Ltd.

Marathon Pharmaceuticals, LLC

MedAnnex Ltd

MedDay SA

Medestea Research & Production S.p.A.

MedImmune, LLC

Meiji Seika Pharma Co., Ltd.

Merck KGaA

Meta-IQ ApS

Mitochon Pharmaceuticals, Inc.

Mitsubishi Tanabe Pharma Corporation

MorphoSys AG

Neuralstem, Inc.

Neuren Pharmaceuticals Limited

Neurotec Pharma SL

New World Laboratories, Inc.

Novartis AG

NovImmune SA

Nuevolution AB

Octapharma AG

Omeros Corporation

OncoImmune, Inc.

Opexa Therapeutics, Inc.

OPKO Health, Inc.

OSE Immunotherapeutics

Parvus Therapeutics, Inc.

Peptinov SAS

Pfenex Inc.

Pfizer Inc.

PharmaEssentia Corporation

PharmatrophiX, Inc.

Pharmaxis Limited

Pieris Pharmaceuticals, Inc.

Plexxikon Inc.

ProNoxis AB

Prothena Corporation Plc

Q Therapeutics, Inc.

ReceptoPharm, Inc.

RedHill Biopharma Ltd.

RegeneRx Biopharmaceuticals, Inc.

Regenesance BV

Resverlogix Corp.

ReveraGen BioPharma, Inc.

Rigel Pharmaceuticals, Inc.

SanBio, Inc.

Santhera Pharmaceuticals Holding AG

Sareum Holdings Plc

SK Biopharmaceuticals Co., Ltd.

Sorrento Therapeutics, Inc.

Symic Biomedical, Inc.

Synthon Holdings BV

Targazyme, Inc.

Teikoku Pharma USA, Inc.

Teva Pharmaceutical Industries Ltd.

Therapix Biosciences Ltd

TikoMed AB

Toleranzia AB

Topas Therapeutics GmbH

TxCell SA

Vaccinex, Inc.

Vakzine Projekt Management GmbH

Vertex Pharmaceuticals Incorporated

Virogenomics BioDevelopment, Inc.

Vitae Pharmaceuticals, Inc.

VivaCell Biotechnology Espana S.L.

Xenetic Biosciences (UK) Limited

XL-protein GmbH

Yungjin Pharm. Co., Ltd.

Zydus Cadila Healthcare Limited

Multiple Sclerosis Therapeutic Products under Development, Key Players in Multiple Sclerosis Therapeutics, Multiple Sclerosis Pipeline Overview, Multiple Sclerosis Pipeline, Multiple Sclerosis Pipeline Assessment

select a license

Single User License
USD 2500 INR 159575
Site License
USD 5000 INR 319150
Corporate User License
USD 7500 INR 478725

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com